Zacks: Brokerages Expect ContraFect Corp (CFRX) to Post -$0.11 EPS

Brokerages expect ContraFect Corp (NASDAQ:CFRX) to announce earnings per share (EPS) of ($0.11) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ContraFect’s earnings, with estimates ranging from ($0.11) to ($0.09). ContraFect posted earnings of ($0.09) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 22.2%. The firm is expected to report its next quarterly earnings report on Thursday, May 9th.

On average, analysts expect that ContraFect will report full year earnings of ($0.38) per share for the current financial year, with EPS estimates ranging from ($0.44) to ($0.31). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.45) per share, with EPS estimates ranging from ($0.52) to ($0.36). Zacks’ earnings per share averages are an average based on a survey of research firms that follow ContraFect.

ContraFect (NASDAQ:CFRX) last announced its quarterly earnings data on Thursday, March 14th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.17.

Shares of NASDAQ:CFRX opened at $0.56 on Friday. ContraFect has a 1-year low of $0.35 and a 1-year high of $2.93.

A number of large investors have recently made changes to their positions in CFRX. Vanguard Group Inc raised its holdings in ContraFect by 24.2% during the 3rd quarter. Vanguard Group Inc now owns 2,634,428 shares of the biotechnology company’s stock worth $5,454,000 after purchasing an additional 512,940 shares during the last quarter. Vanguard Group Inc. raised its holdings in ContraFect by 24.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,634,428 shares of the biotechnology company’s stock worth $5,454,000 after purchasing an additional 512,940 shares during the last quarter. Federated Investors Inc. PA raised its holdings in ContraFect by 6.8% during the 3rd quarter. Federated Investors Inc. PA now owns 6,407,500 shares of the biotechnology company’s stock worth $13,264,000 after purchasing an additional 407,500 shares during the last quarter. Renaissance Technologies LLC raised its holdings in ContraFect by 109.8% during the 3rd quarter. Renaissance Technologies LLC now owns 420,700 shares of the biotechnology company’s stock worth $871,000 after purchasing an additional 220,200 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in ContraFect by 108.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 167,182 shares of the biotechnology company’s stock worth $346,000 after purchasing an additional 86,848 shares during the last quarter. 55.57% of the stock is owned by hedge funds and other institutional investors.

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Recommended Story: Technical Analysis of Stocks, How Can It Help

Get a free copy of the Zacks research report on ContraFect (CFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit